Galleri by GRAIL
High-risk individuals wanting comprehensive screening
Test Performance
Sensitivity
>70% for the 12 deadliest cancers
Specificity
99.6% (0.4% false positive rate)
Detection Method
cfDNA methylation
Turnaround
10-14 days
Key Features
Detects 50+ cancer types • Predicts cancer signal origin • Single blood draw • Available with Rx
Who It's For
Important Notes
Detects a signal shared by 50+ cancers. GRAIL now leads with >70% sensitivity across the 12 cancers causing two-thirds of US cancer deaths (pancreatic 83.7%, liver/bile duct 93.5%, ovary 83.1%). PPV ~62%, cancer signal origin accuracy 93.4%. List $949;self-pay $799 via participating providers. Not covered by Medicare or most plans;assistance up to $350 off at or below 400% FPL. PMA submitted January 2026 with an FDA advisory committee meeting set for 23 September 2026.
Learn more about Galleri by GRAIL
Discuss with your physician before ordering.
Visit Galleri by GRAILCompare All